bioRxiv · 10.1101/2024.11.13.623229
Unbiased discovery of antibody therapies that stimulate macrophage-mediated destruction of B-cell lymphoma
Abstract
Macrophages are critical effectors of antibody therapies for lymphoma, but the best targets for this purpose remain unknown. Here, we sought to define a comprehensive repertoire of cell surface antigens that can be targeted to stimulate macrophage-mediated destruction of B-cell lymphoma. We developed a high-throughput assay to screen hundreds of antibodies for their ability to provoke macrophages to attack B-cell lymphoma cells. Across both mouse and human systems, we identified multiple unappreciated targets of opsonization as well as putative immune checkpoints. We used this information to engineer a compendium of 156 bispecific antibodies, and we identified dozens of bispecifics that dramatically stimulate macrophage-mediated cytotoxicity of lymphoma cells. Among these, a bispecific comprising a SIRP decoy domain and a CD38-targeting arm (WTa2d1xCD38) exhibited maximal efficacy while minimizing the risk of hematologic toxicity. This bispecific stimulated robust anti-tumor responses in multiple xenograft models of aggressive B-cell lymphoma. Our approach can be directly applied to other cancers to rapidly discover bispecific antibodies that leverage anti-tumor responses by macrophages or other innate immune cells.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Ribeiro, J., Pages-Geli, C., Meglan, A., Velarde, J., Blandin, J., Vaccaro, K., Wienclaw, T., Fernandez-Guzman, P., Hahn, C. K., Crespo, M., Weiskopf, K.. 2024-11-15. Unbiased discovery of antibody therapies that stimulate macrophage-mediated destruction of B-cell lymphoma. https://doi.org/10.1101/2024.11.13.623229
Cite the original work for its findings. Save a collection to share your selection of sources.